The results of this clinical trial suggest that the CD44+/CD24− phenotype may be used as a predictor of clinical outcome, and as a predictor of response to Trastuzumab treatment in patients with HER2-positive primary BC [146]. Here, ERBB2 is linked to breast cancer.